No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
HAE241220P40000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover0.00%IV46.98%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma116.06Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Haemonetics: Strong Market Position and Attractive Investment Opportunity Amid Growth in Plasma and Hospital Segments
Investors Three-year Returns in Haemonetics (NYSE:HAE) Have Not Grown Faster Than the Company's Underlying Earnings Growth
Should You Continue to Hold TMO Stock in Your Portfolio?
Are Investors Undervaluing Haemonetics (HAE) Right Now?
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)